Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab Combinations vs EPd/PVd in Relapsed or Refractory Multiple Myeloma
2022-502446-27-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised trial of talquetamab, teclistamab, pomalidomide, elotuzumab, bortezomib and 1 more in multiple myeloma (MM) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Planned start Feb 2024; status: authorised.
02
Drugs
talquetamabteclistamabpomalidomideelotuzumabbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-502446-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502446-27-00.